Figure 4:
Improvement in itch severity and itch-related QoL with difelikefalin versus placebo, measured by (a) ≤3-point improvement in WI-NRS, (b) weekly improvement in WI-NRS, (c) Skindex-10 and (d) 5-D itch scale. SE, standard error. References: Fishbane et al. N Engl J Med 2020;382:222–32; Wooldridge et al. J Am Soc Nephrol 2020;31:22–23.